Vanda Pharmaceuticals (VNDA)

• Market cap: $266M
• 1 day: -1.96%
• 5 days: -3.01%
• 1 month: 4.64%
• 3 months: -2.59%
• 6 months: -8.89%
• Year to date: -6.43%
• 1 year: -9.62%
• 5 years: -53.84%
• 10 years: -65.99%
• Sector: Healthcare
• Industry: Biotechnology

About: Vanda Pharmaceuticals Inc is a biopharmaceutical company engaged in the development and commercialization of therapies to address high unmet medical needs and improve the lives of patients. Its commercial portfolio comprises three products; HETLIOZ for the treatment of Non-24-Hour Sleep-Wake Disorder (Non-24) & nighttime sleep disturbances in Smith-Magenis Syndrome (SMS); Fanapt for the treatment of schizophrenia; and PONVORY. Its other products include VHX-896, ASO Molecules, VQW-765, Tradipitant, VTR-297 and VHX-896. The majority of revenue is derived from the Fanapt product sales. Geographically, the company sells its product predominantly in the United States, and also in Israel, Europe, and Canada.

Employees: 368

Fund manager confidence

Based on 2025 Q2 regulatory disclosures by fund managers ($100M+ AUM)

5% more capital invested

Capital invested by funds: $202M [Q1] → $212M (+$10.8M) [Q2]

1.05% more ownership

Funds ownership: 75.32% [Q1] → 76.37% (+1.05%) [Q2]

9% more repeat investments, than reductions

Existing positions increased: 49 | Existing positions reduced: 45

5% less funds holding

Funds holding: 146 [Q1] → 139 (-7) [Q2]

25% less first-time investments, than exits

New positions opened: 21 | Existing positions closed: 28

97% less call options, than puts

Call options by funds: $197K | Put options by funds: $6.06M

Research analyst outlook

1 Wall Street Analyst provided 1 year price targets over the past 3 months

• Low target: $20
• Avg. target: $20
• High target: $20

1 analyst rating

• positive: 1 100%
• neutral: 0 0%
• negative: 0 0%

HC Wainwright & Co. Raghuram Selvaraju

$20

Buy Reiterated

21 Aug 2025